Eohilia™
Drug - Eohilia™ (budesonide oral suspension) [Takeda Pharmaceuticals, Inc.]
January 2025
Therapeutic area - Glucocorticoids, Oral
Approval criteria
- Patient is at least 11 years of age; AND
- Eohilia is prescribed by, or in consultation with, a gastroenterologist, allergist or immunologist; AND
- Patient has a diagnosis of eosinophilic esophagitis as confirmed in patient’s chart notes; AND
- Patient has received at least 8 weeks of therapy with a proton pump inhibitor; AND
- Patient has tried dietary modifications to managed eosinophilic esophagitis.
- Approval is for 90 days
Quantity limits
- 60 unit-dose packets per 30 days per fill
- Maximum of 3 fills
Background
Eohilia is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). Eohilia has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks.
Questions?
Provider Call Center (844) 575-7887